I-Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Ikhwalithi ephezulu
I-Molnupiravir Yokuhlinzeka Ngezohwebo kanye Nezixhumanisi Ezihlobene Nekhwalithi Ephezulu
Uridine CAS 58-96-8
I-Cytidine CAS 65-46-3
I-Molnupiravir N-1 CAS 2346620-55-9
I-Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Igama Lekhemikhali | I-Molnupiravir (EIDD-2801) |
| Omqondofana | I-MK-4482;i-β-D-N4-Hydroxycytidine-5'-isopropyl ester;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2 -yl) i-methyl isobutyrate |
| Inombolo ye-CAS | 2349386-89-4 |
| Inombolo yeCAT | I-RF-API97 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C13H19N3O7 |
| Isisindo samangqamuzana | 329.31 |
| Ukuncibilika | I-Soluble ku-DMSO |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | Impushana Emhlophe Kuya Kumhlophe |
| Ukuhlonza IR | Isampula ye-Spectrum ihambisana naleyo yezinga lokubhekisela |
| Ukuhlonza HPLC | Isikhathi sokugcina sesiqongo esikhulu sesixazululo sesampula sihambisana naleso sesixazululo esijwayelekile |
| Izinto Ezihlobene | |
| Ukungcola A | ≤0.15% |
| Ukungcola B | ≤0.15% |
| Noma Ikuphi Ukungcola Okungashiwongo | ≤0.15% |
| Isamba Sokungcola Okungashiwongo | ≤0.30% |
| Ukungcola Okuphelele | ≤0.50% |
| Izincibilikisi Ezisele | |
| I-N-Heptane | ≤5000ppm |
| I-Ethanol | ≤5000ppm |
| I-Isopropyl Acetate | ≤5000ppm |
| I-acetonitrile | ≤410ppm |
| I-Methylene Dichloride | ≤600ppm |
| I-acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Okuqukethwe kwamanzi (KF) | ≤0.50% |
| Izinsalela ekushiseni | ≤0.10% |
| Ukujikeleza kwe-Optical | -7.5° ukuya -9.5° (C=0.5, Methanol) |
| Izinsimbi Ezisindayo | ≤10ppm |
| Ukuhlanzeka / Indlela Yokuhlaziya | ≥99.5% (230nm) |
| Indlela Yokuhlola / Yokuhlaziya | 98.0%~102.0% (HPLC ngokomisiwe) |
| I-Shelf Life | Izinyanga ezingama-24 |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-API, i-Molnupiravir (EIDD-2801) COVID-19 Inhibitor |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, isigubhu seCardboard, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Molnupiravir (EIDD-2801, MK-4482) iyisidakamizwa esitholakala ngomlomo se-ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) esinomphumela obanzi we-antiviral ngokumelene ne-SARS-CoV-2, MERS-CoV, I-SARS-CoV, kanye ne-ejenti eyimbangela ye-COVID-19.I-Molnupiravir ithengiswa ngaphansi kwegama lomkhiqizo i-Lagevrio futhi ngokuvamile njenge-emorivir.I-Molnupiravir ikhonjiswe ukuthi ithuthukisa ukusebenza kwamaphaphu, yehlisa ukuncipha kwesisindo somzimba futhi yehlise inani legciwane emaphashini.Ngaphezu komsebenzi omelene nama-coronavirus, i-Molnupiravir, ocwaningweni lwaselabhorethri, ikhombise umsebenzi wokulwa nomkhuhlane wesizini nezinyoni, igciwane lokuphefumula, i-chikungunya virus, igciwane le-Ebola, igciwane laseVenezuela le-equine encephalitis, kanye negciwane le-Eastern equine encephalitis.I-Molnupiravir ekuqaleni yasungulwa ukuze yelaphe umkhuhlane e-Emory University yinkampani yale nyuvesi ekhiqiza izidakamizwa, iDrug Innovation Ventures at Emory (DRIVE), kodwa kubikwa ukuthi yashiywa ngenxa yokukhathazeka ngokuguqulwa kwezakhi zofuzo.Yabe isitholwa inkampani yase-Miami i-Ridgeback Biotherapeutics, kamuva eyabambisene ne-Merck & Co. ukuze kuthuthukiswe umuthi.I-Molnupiravir yagunyazwa ukusetshenziswa kwezokwelashwa e-United Kingdom ngoNovemba 2021.
